VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.

[1]  Yu Seong Lee,et al.  Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect , 2006, Gene Therapy.

[2]  C. Contag,et al.  Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  F. Motoi,et al.  Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region , 2006, Cancer Gene Therapy.

[4]  Francesco Niola,et al.  Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo , 2005, Cancer Gene Therapy.

[5]  E. Scholar,et al.  Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.

[6]  G. Soff,et al.  Update on angiogenesis inhibitors. , 2005, Current opinion in oncology.

[7]  J. Harmey,et al.  Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF) , 2005, Journal of cellular and molecular medicine.

[8]  B. Rouse,et al.  Blocking mouse MMP-9 production in tumor cells and mouse cornea by short hairpin (sh) RNA encoding plasmids. , 2005, Oligonucleotides.

[9]  Bart Landuyt,et al.  Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.

[10]  K. Strebhardt,et al.  Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. , 2004, Journal of the National Cancer Institute.

[11]  Y. Yuzawa,et al.  A Small Interfering RNA Targeting Vascular Endothelial Growth Factor as Cancer Therapeutics , 2004, Cancer Research.

[12]  Y. Gho,et al.  Capsaicin Inhibits in Vitro and in Vivo Angiogenesis , 2004, Cancer Research.

[13]  C. Bucana,et al.  E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. , 2003, Molecular cancer therapeutics.

[14]  L. Benjamin,et al.  Angiogenesis: Tumorigenesis and the angiogenic switch , 2003, Nature Reviews Cancer.

[15]  I. Kuhn,et al.  Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes , 2002, Cancer Gene Therapy.

[16]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[17]  D. Kirn.  Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of Phase I and II trials , 2001, Expert opinion on biological therapy.

[18]  I. Ganly,et al.  Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status , 2000, Gene Therapy.

[19]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[20]  I. Tannock,et al.  A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer , 2000, Nature Medicine.

[21]  M. Hung,et al.  Inhibition of angiogenesis and induction of apoptosis are involved in E1A-mediated bystander effect and tumor suppression. , 2000, Cancer research.

[22]  M. Gulley,et al.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Y. G. Kwon,et al.  Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. , 1999, Biochemical and biophysical research communications.

[24]  M. Mehtali,et al.  Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli , 1996, Journal of virology.

[25]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[26]  R. Nicosia,et al.  Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: A comparative study of angiogenesis in Matrigel, collagen, fibrin, and plasma clot , 1990, In Vitro Cellular & Developmental Biology.

[27]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[28]  Hoguen Kim,et al.  ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis , 2005, Cancer Gene Therapy.

[29]  Martin Vanderlaan,et al.  Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro , 2004, Angiogenesis.

[30]  D. Gray,et al.  The reduction of Raf-1 protein by phosphorothioate ODNs and siRNAs targeted to the same two mRNA sequences. , 2003, Oligonucleotides.

[31]  H. Pehamberger,et al.  Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. , 2003, Oligonucleotides.

[32]  D. Kirn.  Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? , 2001, Gene Therapy.

[33]  D. Carbone,et al.  VEGF as a mediator of tumor-associated immunodeficiency , 2001, Immunologic research.

[34]  M. Gulley,et al.  Erratum: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer (Clinical Cancer Research (2000) 6 (798-806)) , 2000 .

[35]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.